Details for Patent: 11,324,753
✉ Email this page to a colleague
Which drugs does patent 11,324,753 protect, and when does it expire?
Patent 11,324,753 protects QELBREE and is included in one NDA.
This patent has four patent family members in four countries.
Summary for Patent: 11,324,753
| Title: | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
| Abstract: | The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. |
| Inventor(s): | Christopher D. Breder |
| Assignee: | Supernus Pharmaceuticals Inc |
| Application Number: | US15/615,423 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,324,753 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,324,753
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-001 | Apr 2, 2021 | RX | Yes | No | 11,324,753 | ⤷ Start Trial | FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Start Trial | ||||
| Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-002 | Apr 2, 2021 | RX | Yes | No | 11,324,753 | ⤷ Start Trial | FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Start Trial | ||||
| Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-003 | Apr 2, 2021 | RX | Yes | Yes | 11,324,753 | ⤷ Start Trial | FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,324,753
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2735934 | ⤷ Start Trial | |||
| European Patent Office | 2341912 | ⤷ Start Trial | |||
| Spain | 2459322 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2010028207 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
